sellWeak cluster of 410b5-1 plan
Deborah Ann Miller sold $2.2M of NUVL
Chief Legal Officer at Nuvalent, Inc.. 21,800 shares at an average of $103.16, traded Oct 30, 2025, filed Oct 31, 2025.
Warning score
30Value
$2.2M
21,800 shares
Holdings after
49,086
-31% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$2.2M at market
- +10Share of holdings soldSold 31% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-260856, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 30, 2025 | MOption exercise Class A Common Stock10b5-1 | +21,800 | $6.89 | $150k | 70,886 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -700 | $96.65 | $68k | 70,186 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,273 | $97.98 | $125k | 68,913 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -500 | $99.66 | $50k | 68,413 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -600 | $100.96 | $61k | 67,813 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -2,121 | $102.00 | $216k | 65,692 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -3,733 | $102.88 | $384k | 61,959 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -3,491 | $103.90 | $363k | 58,468 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -9,382 | $104.78 | $983k | 49,086 | Oct 31, 2025 |
| Oct 30, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -21,800 | $0.00 | $0 | 118,808 | Oct 31, 2025 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $261k 2,111 shares | -3% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.4M 11,430 shares | -12% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.8M 23,000 shares | -28% | |
| 16Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $679k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.5M 20,000 shares | -26% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $2.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $593k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $593k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.